Shares of Mankind Pharma Ltd gained nearly 2% on Wednesday, rising to ₹2,616.70, after the company announced a landmark collaboration with OpenAI to institutionalise artificial intelligence (AI) across its value chain.
The Delhi-based pharmaceutical major said it will integrate OpenAI Enterprise into multiple verticals, including field force enablement, digital marketing, research and development (R&D), manufacturing, and medical affairs. According to executives, GPT-powered dashboards will be deployed to deliver real-time insights across R&D, supply chain, and commercial operations.
The initiative, which insiders said has been in the works for some time, will also focus on advanced clinical intelligence. By streamlining literature reviews and drawing insights from clinical and genomic data, the collaboration is expected to accelerate scientific discovery and decision-making processes.
The move aligns with a broader global trend of large pharmaceutical companies embedding generative AI into drug discovery, clinical trials, and manufacturing. Peers such as Merck and Pfizer have already adopted similar AI-driven approaches to enhance efficiency and patient engagement.
At the time of writing, Mankind Pharma shares were trading 1.81% higher at ₹2,616.70 on NSE, compared to the previous close of ₹2,570.20.
